author-photo

Brandi Reeves

University of North Carolina at Chapel Hill

42

Papers

710

Citations

Citation Trend

Filter By

Papers (28) Sort By

Journal Conference Others

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (1)
Cancer Therapy-Associated Thrombosis.

2021 Arteriosclerosis, Thrombosis, and Vascular Biology
Show All
- Source
- Cite
- Save
Citations (2)
P-Selectin Deficiency Reduces Acute Vascular Complications but Not Chronic Organ Damage in Sickle Cell Mice

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (4)
Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Thrombosis in myeloproliferative neoplasms: update in pathophysiology.

2021 Current Opinion in Hematology
- Brandi Reeves
- Alison R. Moliterno
Show All
- Source
- Cite
- Save
Citations (1)
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (158)
MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)